$2.56
1.16% today
Nasdaq, Feb 05, 04:17 pm CET
ISIN
US17322U2078
Symbol
CTXR
Sector
Industry

Citius Pharmaceuticals Inc Stock price

$2.59
-1.32 33.76% 1M
-20.72 88.89% 6M
-1.41 35.25% YTD
-12.41 82.73% 1Y
-35.16 93.14% 3Y
-25.41 90.75% 5Y
-466.16 99.45% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.10 3.72%
ISIN
US17322U2078
Symbol
CTXR
Sector
Industry

Key metrics

Market capitalization $22.26m
Enterprise Value $23.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.27
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-42.00m
Free Cash Flow (TTM) Free Cash Flow $-28.20m
Cash position $3.25m
EPS (TTM) EPS $-5.95
P/E forward negative
P/S forward 0.56
EV/Sales forward 0.59
Short interest 7.00%
Show more

Is Citius Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Citius Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Citius Pharmaceuticals Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Citius Pharmaceuticals Inc forecast:

Buy
100%

Financial data from Citius Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.21 0.21
11% 11%
-
-0.21 -0.21
11% 11%
-
- Selling and Administrative Expenses 30 30
38% 38%
-
- Research and Development Expense 12 12
20% 20%
-
-42 -42
14% 14%
-
- Depreciation and Amortization 0.21 0.21
11% 11%
-
EBIT (Operating Income) EBIT -42 -42
14% 14%
-
Net Profit -39 -39
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Citius Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Citius Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
28 days ago
CRANFORD, N.J. , Jan. 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of its common stock and accompanying ...
Neutral
PRNewsWire
29 days ago
CRANFORD, N.J. , Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (...
Neutral
PRNewsWire
about one month ago
CRANFORD, N.J. , Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value.
More Citius Pharmaceuticals Inc News

Company Profile

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Head office United States
CEO Leonard Mazur
Employees 23
Founded 2007
Website www.citiuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today